Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07459660 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

An Open-Label Study of ML-007C-MA in Adults With Alzheimer's Disease Psychosis

StatusEnrolling by Invitation
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial status changed: Recruiting → Enrolling by Invitation
    • Site details revised at 8 of 8 sites
    v4
  2. Trial sites expanded: 3 → 8 locationsv3
  3. Recruitment opened
    • Trial sites expanded: 0 → 3 locations
    • Start date changed from estimate of Mar 2026 to Mar 25, 2026
    v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
ML-007C-MA-222 is a 52-week, flexible-dose, open-label extension study designed to evaluate the long-term safety, tolerability, and effectiveness of ML007C-MA in participants with ADP who have completed the antecedent study (ie, Study ML-007C-MA-221).
Trial Details
NCT Number NCT07459660
Lead Sponsor MapLight Therapeutics
Conditions
(from sponsor)		 Psychosis Associated With Alzheimer's Disease
Related terms Alzheimer Disease, Brain Diseases, Central Nervous System Diseases, Delusions, Dementia, Hallucinations, Mental Disorders, Nervous System Diseases, Neurocognitive Disorders, Neurodegenerative Diseases, Psychotic Disorders, Schizophrenia Spectrum and Other Psychotic Disorders, Tauopathies
Enrollment 210 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov